Payment overview · 2025
General Payments
$317.70
12 reported records · 7 companies
Healthcare provider profile · identity verified
Hsiao Bechinski, DO
Allopathic & Osteopathic Physicians|Internal Medicine · CLARKSTON, MI · NPI 1861594962
Verified facts
What the public records show
CMS Open Payments records show Hsiao Bechinski, DO received $317.70 in general payments during 2025 across 12 reported records.
Edwards Lifesciences Corporation accounted for 36.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Nurtec Odt, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $116.57 | 36.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.63 | 17.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.33 | 13.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.25 | 10.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.16 | 9.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.24 | 6.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.52 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $317.70 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $116.57 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.69 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.69 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $37.76 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.16 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.16 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 59 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 260 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 254 | 48 |
| Omeprazole | Omeprazole | 171 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 124 | 35 |
| Metformin Hcl | Metformin Hcl | 109 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 23 |
| Gabapentin | Gabapentin | 86 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | suppressed |
| Lisinopril | Lisinopril | 80 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 23 |
| Losartan Potassium | Losartan Potassium | 73 | 16 |
| Sertraline Hcl | Sertraline Hcl | 73 | 13 |
| Tramadol Hcl | Tramadol Hcl | 71 | 17 |
| Meloxicam | Meloxicam | 68 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 13 |
| Simvastatin | Simvastatin | 67 | 15 |
| Celecoxib | Celecoxib | 64 | 22 |
| Furosemide | Furosemide | 64 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 16 |
| Alprazolam | Alprazolam | 63 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 27 |
| Ozempic | Semaglutide | 60 | suppressed |
| Eliquis | Apixaban | 59 | 12 |
| Carvedilol | Carvedilol | 57 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 57 | 21 |
| Buspirone Hcl | Buspirone Hcl | 54 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 13 |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Ibuprofen | Ibuprofen | 50 | 24 |
| Potassium Chloride | Potassium Chloride | 50 | 13 |
| Trazodone Hcl | Trazodone Hcl | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Famotidine | Famotidine | 44 | 14 |
| Azithromycin | Azithromycin | 42 | 31 |
| Ventolin Hfa | Albuterol Sulfate | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Prednisone | Prednisone | 38 | 15 |
| Atenolol | Atenolol | 37 | suppressed |
| Lactulose | Lactulose | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Niacin Er | Niacin | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Lorazepam | Lorazepam | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Np Thyroid | Thyroid,pork | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $317.70 · 12 records | Edwards Lifesciences Corporation | ELIQUIS, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, SAPIEN 3 Ultra RESILIA, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error